Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)
Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –
Aurinia Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Aurinia Pharmaceuticals's cash was $45.79M at Sep 30, 2026. For fiscal 2025 it was $80.21M, down 3.9% from the year before. Over ten years it grew 30.1% a year on average. The highest annual figure on record is $306.02M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.21M | -3.9% |
| FY2024 | Dec 31, 2024 | $83.43M | +71.1% |
| FY2023 | Dec 31, 2023 | $48.76M | -48.2% |
| FY2022 | Dec 31, 2022 | $94.17M | -59.4% |
| FY2021 | Dec 31, 2021 | $231.90M | -14.9% |
| FY2020 | Dec 31, 2020 | $272.35M | -11.0% |
| FY2019 | Dec 31, 2019 | $306.02M | +159.4% |
| FY2018 | Dec 31, 2018 | $117.97M | -28.8% |
| FY2017 | Dec 31, 2017 | $165.63M | +317.7% |
| FY2016 | Dec 31, 2016 | $39.65M | +588.8% |
| FY2015 | Dec 31, 2015 | $5.76M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $45.79M | -37.2% |
| Q2 FY2026 | Jun 30, 2026 | $179.73M | +239.7% |
| Q1 FY2026 | Mar 31, 2026 | $40.75M | -38.4% |
| Q4 FY2025 | Dec 31, 2025 | $80.21M | -3.9% |
| Q3 FY2025 | Sep 30, 2025 | $72.89M | +99.0% |
| Q2 FY2025 | Jun 30, 2025 | $52.91M | +59.1% |
| Q1 FY2025 | Mar 31, 2025 | $66.11M | +3.4% |
| Q4 FY2024 | Dec 31, 2024 | $83.43M | +71.1% |
| Q3 FY2024 | Sep 30, 2024 | $36.63M | -19.6% |
| Q2 FY2024 | Jun 30, 2024 | $33.27M | -59.1% |
| Q1 FY2024 | Mar 31, 2024 | $63.91M | -27.6% |
| Q4 FY2023 | Dec 31, 2023 | $48.76M | -48.2% |
| Q3 FY2023 | Sep 30, 2023 | $45.56M | -46.6% |
| Q2 FY2023 | Jun 30, 2023 | $81.39M | -46.2% |
| Q1 FY2023 | Mar 31, 2023 | $88.33M | -32.9% |
| Q4 FY2022 | Dec 31, 2022 | $94.17M | -59.4% |
| Q3 FY2022 | Sep 30, 2022 | $85.34M | +48.2% |
| Q2 FY2022 | Jun 30, 2022 | $151.41M | +24.6% |
| Q1 FY2022 | Mar 31, 2022 | $131.64M | -15.9% |
| Q4 FY2021 | Dec 31, 2021 | $231.90M | -14.9% |
| Q3 FY2021 | Sep 30, 2021 | $57.59M | -76.9% |
| Q2 FY2021 | Jun 30, 2021 | $121.56M | -47.7% |
| Q1 FY2021 | Mar 31, 2021 | $156.59M | -42.9% |
| Q4 FY2020 | Dec 31, 2020 | $272.35M | -11.0% |
| Q3 FY2020 | Sep 30, 2020 | $248.76M | +110.9% |
| Q2 FY2020 | Jun 30, 2020 | $232.41M | +40.3% |
| Q1 FY2020 | Mar 31, 2020 | $274.21M | +591.6% |
| Q4 FY2019 | Dec 31, 2019 | $306.02M | +5216.5% |
| Q4 FY2018 | Dec 31, 2018 | $117.97M | – |
| Q4 FY2017 | Dec 31, 2017 | $165.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $39.65M | – |
| Q4 FY2015 | Dec 31, 2015 | $5.76M | – |
See a number that looks wrong?